Document is current

Any future updates will be listed below

ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy

Crossref DOI link: https://doi.org/10.1245/s10434-025-17458-8

Published Online: 2025-05-21

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark